Linda Pissott Reig, shareholder in the firm's FDA & Biotechnology practice, comments on the lack of clarity about the pathway for FDA approval of digital health tools, in light of lawmakers' recent letter to the FDA voicing concerns about a new pre-certification pilot program the agency proposed. Linda suggests that "we've been a bit slow on adapting to these new health technologies." Read "Warren Wary of FDA Digital Health Pilot Program with Local Support" in the Boston Business Journal.